IGM Biosciences Inc [IGMS] stock is trading at $9.70, up 3.19%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IGMS shares have gain 43.70% over the last week, with a monthly amount glided 0.52%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
IGM Biosciences Inc [NASDAQ: IGMS] stock has seen the most recent analyst activity on February 09, 2024, when RBC Capital Mkts upgraded its rating to a Outperform and also boosted its price target to $21 from $9. Previously, BofA Securities downgraded its rating to Neutral on December 15, 2023, and kept the price target unchanged to $8. On December 07, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. JP Morgan initiated its recommendation with a Neutral and recommended $27 as its price target on October 17, 2022. BofA Securities started tracking with a Buy rating for this stock on August 29, 2022, and assigned it a price target of $34. In a note dated December 13, 2021, RBC Capital Mkts downgraded an Sector Perform rating on this stock but restated the target price of $51.
IGM Biosciences Inc [IGMS] stock has fluctuated between $3.81 and $17.70 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. IGM Biosciences Inc [NASDAQ: IGMS] shares were valued at $9.70 at the most recent close of the market. An investor can expect a potential return of 250.52% based on the average IGMS price forecast.
Analyzing the IGMS fundamentals
IGM Biosciences Inc [NASDAQ:IGMS] reported sales of 2.13M for the trailing twelve months, which represents a growth of 75.00%. Gross Profit Margin for this corporation currently stands at -4.14% with Operating Profit Margin at -123.69%, Pretax Profit Margin comes in at -115.37%, and Net Profit Margin reading is -115.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -1.03 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.23 points at the first support level, and at 8.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.32, and for the 2nd resistance point, it is at 10.94.
IGM Biosciences Inc [IGMS] reported earnings per share of -$1.01 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.03/share, meaning a difference of $0.02 and a surprise factor of 1.90%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$1.04 per share as compared to estimates of -$1.21 per share, a difference of $0.17 representing a surprise of 14.00%.
Ratios To Look Out For
For context, IGM Biosciences Inc’s Current Ratio is 8.18. In addition, the Quick Ratio stands at 8.18 and the Cash Ratio stands at 2.66. Considering the valuation of this stock, the price to sales ratio is 268.46, the price to book ratio is 2.80.
Transactions by insiders
Recent insider trading involved BAKER BROS. ADVISORS LP, Director, that happened on Mar 28 ’24 when 97473.0 shares were purchased. Director, BAKER BROS. ADVISORS LP completed a deal on Mar 27 ’24 to buy 27844.0 shares. Meanwhile, Director BAKER BROS. ADVISORS LP bought 0.27 million shares on Mar 26 ’24.
